miR-33 inhibition (beta cell-specific)

miR-33 inhibition (beta cell-specific) is an experimental therapeutic approach aimed at silencing microRNA-33 (miR-33) selectively within pancreatic beta cells to treat type 2 diabetes and improve islet function. miR-33 is an intronic microRNA that post-transcriptionally represses genes involved in lipid metabolism and insulin secretion, most notably the cholesterol transporter ABCA1. While global miR-33 deficiency can lead to adverse systemic metabolic effects such as diet-induced obesity and hepatic steatosis, selective beta-cell deletion or targeted inhibition of miR-33 has been shown in preclinical models to enhance glucose-stimulated insulin secretion, increase beta-cell mass and proliferation, and protect against cytokine-induced apoptosis. This localized targeting strategy represents a promising avenue for preserving beta-cell function without triggering systemic lipid dysregulation.

Other names

beta cell-specific miR-33 inhibitionislet-specific miR-33 inhibitionmiR-33 knockdown (beta cell-specific)miR-33 silencing (beta cell-specific)